
Figure 1/8


5-FormylTHF
MTHFS
5,10-MethenylTHF
MTHFD
5,10-MethyleneTHF
MTHFR
5-MethylTHF
METHYLATION REACTIONS
PURINES
dUMP
TS
dTMP
DNA SYNTHESIS
DHF
DHFR
THF
SHMT1

Response rates according to RECIST 1.1 in 12 first line patients and one 2nd line patient in the ISO-CC-005 study after 8 weeks treatment





Figure 2/8

Figure 3/8


Increase of plasma dUrd at 24 hours, pmol/ml
100
90
80
70
60
50
40
30
20
10
0
LLV 30
6R 30
6R 60

5

Figure 4/8



Plasma dUrd (%) relative to LV 60 mg/m2
100
90
80
70
60
50
40
30
20
10
0
6R 30
6R 60

Figure 5/8




Figure 6/8

5




Figure 7/8




ORR data from first line mCRC patients in the ISO-CC-005 study
% change of tumor size from baseline at week 8 and 16
ISO-CC-005 - 8 and 16 weeks after treatment initiation:
No patient with tumor progression between 8 and 16 weeks
All patients with PR at 8 weeks are maintained in PR at 16 weeks
Missing data in 4 patients (initial protocol design not following patients for w16)
Missing data w16
Missing data w16
Missing data w16
Partial Response (PR)
Stable disease (SD)
Week 8
Week 16
60 mg MOD+FOLFIRI
240 mg MOD+5FU
30 mg MOD+FOLFIRI
60 mg MOD+FOLFOX
60 mg MOFOX
60 mg MOFOX
30 mg MOD+5FU
30 mg MOD+FOLFIRI
30 mg MOD+5FU
60 mg MOD+5FU
60 mg MOD+5FU
20%
0%
-20%
-40%
-60%
-80%
-100%

Figure 8/8



	CoFactor/ 5-FU (n= 147)	Leucovorin /5-FU (n= 148)	P-value
Patients reporting at least 1 hematological or gastrointestinal adverse event of grade 3 or greater	23	10	p< 0.05
Hematological	11	7	
Gastrointestinal	12	5	

ADVENTRX PHARMACEUTICALS

	CoFactor/5-FU (n= 150)	Leucovorin /5-FU (n= 150)
Objective response rate	10.7%	13.3%
Median Progression-free Survival (months)	6.3mo	6.1mo
Preliminary Median Survival (months)	14.7mo	14.3mo